Pyridoxal 5-phosphate vitamin B6: what the data says

Pyridoxal 5-phosphate — P-5-P for short — is the biologically active coenzyme form of vitamin B6. Most cheap supplements use pyridoxine hydrochloride instead, which your liver still has to convert. Plasma P-5-P concentration is the gold-standard marker of B6 status, and studies suggest that even people eating adequate diets can show functional shortfalls when that conversion step is compromised. Here is what the evidence actually looks like.

evidence-actually-shows">What the evidence actually shows

The first thing worth saying is that B6 research is messier than the supplement industry implies. Most studies measure dietary intake or plasma pyridoxal 5-phosphate levels and look for associations — they are not randomised controlled trials feeding people P-5-P capsules and measuring hard outcomes. That matters when you are trying to work out what supplementation actually does.

That said, the observational data is interesting. Lu et al. (2024) analysed NHANES data from 4,925 US adults and found that both higher dietary B6 intake and higher plasma P-5-P were associated with significantly lower odds of depression — with those in the highest plasma P-5-P quartile showing roughly 34% lower odds compared to the lowest quartile (OR 0.66, 95% CI 0.50–0.88). That is an association, not causation, but it is a reasonably sized dataset and the dose-response relationship held after adjustment for confounders.

On the metabolic side, Kim et al. (2022) found that plasma P-5-P levels were positively associated with omega-3 polyunsaturated fatty acid concentrations in older US adults — specifically EPA and DHA. The mechanism proposed is that P-5-P-dependent enzymes are involved in fatty acid desaturation and elongation pathways. This is speculative territory for direct supplementation claims, but it points to how broadly P-5-P is woven into metabolic function.

And Gregory et al. (2017) make the point clearly in their review: cellular availability of pyridoxal 5-phosphate governs the transsulfuration pathway — the route by which homocysteine is converted to cysteine. When P-5-P is low, this pathway slows, and homocysteine can accumulate. That is not a minor footnote; elevated homocysteine is a well-established cardiovascular risk marker.

The biology: what P-5-P is actually doing in your cells

Vitamin B6 is not one compound. It is a family of six interconvertible vitamers — pyridoxine, pyridoxal, pyridoxamine, and their phosphorylated forms. Of these, pyridoxal 5-phosphate is the one that actually works. Everything else is a precursor that needs converting.

The enzyme responsible for the final conversion step is pyridox(am)ine 5-phosphate oxidase (PNPO). Rivero et al. (2024) examined species-specific features of this enzyme and found meaningful variation in its efficiency — which partly explains why some individuals appear to have suboptimal P-5-P status even when dietary B6 intake looks adequate on paper. If your PNPO activity is lower, you may convert pyridoxine to P-5-P less efficiently.

Once inside the cell, P-5-P acts as a coenzyme for over 150 enzymatic reactions. These include transamination (moving amino groups between molecules), decarboxylation (making neurotransmitters like serotonin, dopamine, and GABA from their amino acid precursors), and the transsulfuration reactions mentioned above. It is also required for glycogen phosphorylase, the enzyme that liberates glucose from stored glycogen — which is why Vitamin B6 contributes to normal energy-yielding metabolism is not just marketing language; it reflects a real biochemical role.

Mitochondria are a particularly important site. Pena et al. (2025) identified that the mitochondrial carrier protein SLC25A38 is required for P-5-P accumulation inside mitochondria — and that without adequate mitochondrial P-5-P, several aspects of oxidative metabolism may be compromised. Ciapaite et al. (2023) extended this, showing in cell models that P-5-P homeostasis is directly linked to mitochondrial oxidative function. This is early-stage research, but the direction is consistent.

P-5-P versus pyridoxine: does the form actually matter?

This is the question I get asked most often about B6, and the honest answer is: probably yes, for some people, but not dramatically for most healthy adults with normal liver function.

When you take pyridoxine hydrochloride — the standard cheap form — it gets absorbed in the small intestine, travels to the liver, and is phosphorylated and oxidised into P-5-P. This conversion is generally efficient in healthy people. However, there are situations where it may be less so: liver dysfunction, genetic variants affecting PNPO activity, inflammatory states (which can reduce PNPO expression), and ageing.

Ito et al. (2022) studied what happens when P-5-P-binding proteins are deficient — a rare genetic condition — and found that pyridoxine 5-phosphate accumulates rather than being converted to P-5-P. This is a clinical edge case, but it illustrates that the conversion step is a real bottleneck, not a theoretical one.

For neurological applications, the distinction appears more significant. Akiyama et al. (2021) found that in the context of B6-dependent epilepsy, pyridoxal in cerebrospinal fluid may be a more informative marker than P-5-P itself — suggesting the brain's handling of B6 vitamers is distinct from peripheral metabolism. This is a specialist clinical area, but it reinforces the idea that form and site of action both matter.

For a daily vitamin powder or general supplement context, using P-5-P directly removes the conversion step entirely. That is why the KōJō Daily Formula uses 2.8mg of B6 in the P-5-P form — it is not a marketing distinction, it is just the more direct route to the active coenzyme.

Dosing: what the clinical evidence supports

The EU Nutrient Reference Value for vitamin B6 is 1.4mg per day for adults. The UK Safe Upper Level, set by the Expert Group on Vitamins and Minerals, is 10mg per day from supplements (separate from dietary intake). Above 200mg per day — doses that were used historically in high-dose PMS trials — peripheral neuropathy has been reported, though this is almost exclusively at pharmacological rather than nutritional doses.

Most RCTs looking at B6 supplementation for functional outcomes have used doses in the 1.5–25mg range. For mood and neurotransmitter-related outcomes, doses of around 2–10mg appear in the literature. Lu et al. (2024) found the association with lower depression scores was evident across the dietary intake range, not just at high doses — suggesting that correcting inadequacy matters more than megadosing.

For cardiovascular-adjacent outcomes, Dhalla et al. (2013) reviewed mechanisms by which B6 and P-5-P may support cardiac performance in the context of ischaemic heart disease, noting roles in calcium handling and energy metabolism — though this is mechanistic and animal data rather than large human RCT evidence, and I would be overstating it to claim clinical benefit from those findings alone.

The blood pressure angle is newer and tentative. Lellig et al. (2025) reviewed P-5-P as a potential candidate for hypertensive patients, pointing to its role in nitric oxide synthesis pathways and vascular smooth muscle function. The human data on this is thin, and I would not take P-5-P specifically for blood pressure on the current evidence. But the mechanistic rationale is worth watching.

At 2.8mg of P-5-P, the KōJō dose sits comfortably above the NRV (200% NRV), well within the safe upper level, and in the range where functional coenzyme availability is likely to be meaningfully supported — particularly for people whose conversion from pyridoxine is less efficient.

B6 and the nervous system: the neurotransmitter connection

This is probably the area where the mechanistic case for P-5-P is strongest, even if the direct supplementation RCT evidence remains limited.

P-5-P is the coenzyme for aromatic L-amino acid decarboxylase — the enzyme that converts 5-hydroxytryptophan to serotonin and L-DOPA to dopamine. It is also required for glutamate decarboxylase, which makes GABA from glutamate. Without adequate P-5-P, these conversions may be less efficient. The clinical expression of severe deficiency — pyridoxine-dependent epilepsy — is essentially a failure of GABA synthesis, which illustrates how directly P-5-P underpins inhibitory neurotransmission.

Vu et al. (2022) used a B6 antagonist to map genetic connections between P-5-P and mitochondrial function, finding links to one-carbon metabolism — the folate and methionine cycle that underpins methylation reactions throughout the body. This is basic science rather than clinical data, but it situates P-5-P at the intersection of several pathways relevant to neurological function.

Vitamin B6 contributes to the reduction of tiredness and fatigue — and this is not simply an energy claim. The neurotransmitter synthesis role means that adequate P-5-P availability may matter for mood regulation as much as for physical energy. These are intertwined.

Who is most likely to have suboptimal B6 status?

Deficiency severe enough to cause clinical symptoms is uncommon in the UK. But functional shortfalls — where plasma P-5-P is low enough to affect enzymatic efficiency without causing overt symptoms — appear more prevalent than most people assume.

Groups worth paying attention to include:

• Older adults — absorption tends to decline with age, and the PNPO conversion step may be less efficient
• People with inflammatory conditions — inflammation can reduce PNPO activity, lowering P-5-P even when dietary intake is adequate
• Those with higher protein intakes — B6 requirements scale with protein consumption, since transamination reactions are central to amino acid metabolism
• People taking certain medications — oral contraceptives, isoniazid, and some anticonvulsants can interfere with B6 metabolism
• Regular alcohol drinkers — alcohol interferes with P-5-P binding to proteins and accelerates its degradation

If you are interested in how B6 fits alongside other nutrients in a broader stack, it is worth reading about the benefits of creatine for men over 40 — creatine synthesis also involves the transsulfuration pathway where B6 plays a supporting role. And for context on fat-soluble vitamins that often appear alongside B6 in daily formulas, the piece on vitamin e drink covers the evidence on vitamin E in a similar format.

What to look for on a supplement label

B6 appears on labels under several names. Here is how to read them:

• Pyridoxine hydrochloride — the most common form. Cheap, stable, effective for most people. Requires hepatic conversion to P-5-P.
• Pyridoxal 5-phosphate (also listed as P-5-P or PLP) — the active coenzyme form. No conversion required. More expensive to manufacture.
• Pyridoxamine — less common in supplements. Also requires conversion.

The dose matters as much as the form. A label showing "Vitamin B6 (as pyridoxal 5-phosphate) 2.8mg" tells you both the form and the amount. Some products list the total B6 equivalent in milligrams, which can obscure whether you are getting a meaningful dose of the active form or a trace amount padded with cheaper vitamers.

Also check where B6 sits relative to the NRV. At 1.4mg NRV, a dose of 2.8mg is 200% NRV — enough to meaningfully support coenzyme availability. A dose of 0.3mg at 21% NRV, which you see in some multivitamins, is unlikely to move the needle if your status is marginal.

Frequently asked questions

My honest take

I spent longer than I expected reading the primary literature on P-5-P before deciding to use it in the KōJō formula. What I found was not a stack of dramatic RCTs showing clear-cut outcomes. It was something more nuanced: a coenzyme so embedded in fundamental biochemistry that its absence shows up in multiple systems at once, and whose active form is genuinely distinct from the cheap precursor most supplements use.

The mood data from Lu et al. (2024) is interesting but observational. The mitochondrial work from Ciapaite et al. (2023) and Pena et al. (2025) is early-stage. The cardiovascular mechanistic work from Dhalla et al. (2013) is mostly animal data. I am not going to tell you P-5-P will change how you feel in a week, because I do not know that and the evidence does not support that claim.

What I do think is reasonable: if you are going to take a B6 supplement at all, using P-5-P at a sensible dose — around 2.8mg — is the more direct approach. It skips a conversion step that is not universally efficient. It sits within the safe upper level with considerable headroom. And it covers the registered claims that actually hold up: Vitamin B6 contributes to normal energy-yielding metabolism, and Vitamin B6 contributes to the reduction of tiredness and fatigue. Those are real, biochemically grounded statements.

The rest — the blood pressure angle, the fatty acid associations, the deeper neurological connections — is worth watching. But I would rather tell you it is preliminary than dress it up as settled science. That is not how I want to run this brand.

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement regimen.